Collegium Pharmaceutical stake reported by Principal Global
Principal Global Investors filed a Schedule 13G reporting a passive ownership position in Collegium Pharmaceutical, Inc. common stock.
Rhea-AI Filing Summary
Principal Global Investors filed a Schedule 13G reporting a passive ownership position in Collegium Pharmaceutical, Inc. common stock. The firm reports beneficial ownership of 1,632,360 shares of common stock, par value $0.001 per share, representing 5% of the outstanding class.
Principal Global Investors has no sole voting or dispositive power over these shares but reports shared voting and shared dispositive power over 1,632,360 shares. The filing identifies Principal Global Investors as a Delaware entity, with its principal office in Des Moines, Iowa, and Collegium Pharmaceutical’s principal executive offices in Stoughton, Massachusetts.
Positive
- None.
Negative
- None.
Key Figures
Key Terms
beneficially owned financial
Schedule 13G regulatory
percent of class financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in Collegium Pharmaceutical (COLL) does Principal Global Investors report?
What is the nature of Principal Global Investors’ ownership in COLL?
Where are Collegium Pharmaceutical (COLL) and Principal Global Investors based?
AI-generated analysis. How Rhea-AI works. Not financial advice.